30486-56-7

Basic information

• Product Name: 1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE
• Synonyms: 1-BENZHYDRYLPERHYDRO-1,4-DIAZEPINE;1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE
• CAS NO: 30486-56-7
• Molecular Formula: C₁₈H₂₂N₂
• Molecular Weight: 266.38
• Mol File: 30486-56-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 377.3 °C at 760 mmHg
• Flash Point: 138.7 °C
• Appearance: /
• Density: 1.051 g/cm³
• Vapor Pressure: 6.83E-06mmHg at 25°C
• Refractive Index: 1.573
• PKA: 10.52±0.20(Predicted)
• CAS DataBase Reference: 1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE(30486-56-7)
• EPA Substance Registry System: 1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE(30486-56-7)

Safety Data

• Hazardous Substances Data: 30486-56-7(Hazardous Substances Data)

Usage

General Description

1-(diphenylmethyl)hexahydro-1H-1,4-diazepine is a chemical compound with the molecular formula C20H26N2. It is a heterocyclic compound belonging to the class of diazepines and is structurally related to benzodiazepines. 1-(DIPHENYLMETHYL)HEXAHYDRO-1H-1,4-DIAZEPINE has been studied for its potential pharmacological activity, particularly as a central nervous system depressant and anxiolytic. It has also been investigated for its potential use in the treatment of anxiety disorders, although its exact mechanism of action and therapeutic potential are not fully understood. The compound's chemical structure features a hexahydro-1,4-diazepine core with a diphenylmethyl substituent, and its potential medicinal properties make it a subject of ongoing research and study in the field of medicinal chemistry.

InChI:InChI=1/C18H22N2/c1-3-8-16(9-4-1)18(17-10-5-2-6-11-17)20-14-7-12-19-13-15-20/h1-6,8-11,18-19H,7,12-15H2

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 776-74-9 Bromodiphenylmethane 
• 90-99-3 diphenylchloromethane 

Downstream Products

• 1221685-58-0 C₂₅H₃₃N₃O 
• 1221685-57-9 C₂₅H₃₂N₂O 
• 1221685-59-1 C₂₃H₃₁N₃O 
• 1221685-60-4 C₂₅H₃₃N₃S 

Relevant articles and documents

Synthesis, Structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds

We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the Structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine.

Hybrid approach for the design of highly affine and selective dopamine D3 receptor ligands using privileged scaffolds of biogenic amine GPCR ligands

A series of compounds containing privileged scaffolds of the known histamine H1 receptor antagonists cetirizine, mianserin, ketotifen, loratadine, and bamipine were synthesized for further optimization as ligands for the related biogenic amine binding dopamine D3 receptor. A pharmacological screening was carried out at dopamine D2 and D3 receptors. In the preliminary testing various ligands have shown moderate to high affinities for dopamine D3receptors, for example, N-(4-{4-[benzyl(phenyl)amino]piperidin-1-yl}butylnaphthalen-2-carboxamide (19a) (hD3 Ki = 0.3 nM; hD2 Ki = 703 nM), leading to a selectivity ratio of 2343.